Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Stopped early · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Non Arteritic Anterior Ischemic Optic Neuropathy

In brief

This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.

Key facts

Study ID
NCT02341560
Run by
Quark Pharmaceuticals
People needed
732
Starts
2016-02-24
Expected to finish
2019-07-01
Last updated by the study team
2020-07-20

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.